Technical Analysis for LYEL - Lyell Immunopharma, Inc.

Grade Last Price % Change Price Change
D 14.81 2.14% 0.31
LYEL closed up 2.14 percent on Monday, August 2, 2021, on 46 percent of normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Flat
Historical LYEL trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
Up 3 Days in a Row Strength 0.00%
New Downtrend Bearish 2.14%
Lower Bollinger Band Walk Weakness 2.14%
Oversold Stochastic Weakness 2.14%
Stochastic Buy Signal Bullish 6.01%
Hot IPO Pullback Bullish Swing Setup 6.01%
NR7 Range Contraction 6.01%
Lower Bollinger Band Walk Weakness 6.01%
Inside Day Range Contraction 6.01%
Older End-of-Day Signals for LYEL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Lyell Immunopharma, Inc. Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.


Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Life Sciences Biology Solid Tumors Non Small Cell Lung Cancer Cell Biology Solid Tumor Treatment Of Non Small Cell Lung Cancer Cloning Induced Stem Cells Stem Cell Developmental Biology Synovial Sarcoma

Is LYEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 18.9
52 Week Low 13.11
Average Volume 453,206
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 15.44
10-Day Moving Average 14.82
Average True Range 1.10
ADX 24.38
+DI 15.15
-DI 18.78
Chandelier Exit (Long, 3 ATRs) 14.06
Chandelier Exit (Short, 3 ATRs) 16.40
Upper Bollinger Bands 17.35
Lower Bollinger Band 13.52
Percent B (%b) 0.34
BandWidth 24.81
MACD Line -0.51
MACD Signal Line -0.37
MACD Histogram -0.1431
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 16.91
Resistance 3 (R3) 17.00 16.38 16.56
Resistance 2 (R2) 16.38 15.85 16.34 16.44
Resistance 1 (R1) 15.60 15.52 15.29 15.51 16.33
Pivot Point 14.98 14.98 14.83 14.94 14.98
Support 1 (S1) 14.20 14.45 13.89 14.11 13.29
Support 2 (S2) 13.58 14.12 13.54 13.18
Support 3 (S3) 12.80 13.58 13.06
Support 4 (S4) 12.71